EC
SPRY icon

EcoR1 Capital’s ARS Pharmaceuticals SPRY Stock Holding History

EcoR1 Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-575,359
Closed -$2.44M – 85
2022
Q2 		$2.44M Buy
575,359
+245,822
+75% +$857K 0.08% 56
2022
Q1 		$1.16M Sell
329,537
-730,473
-69% -$3.18M 0.04% 74
2021
Q4 		$7.06M Sell
1,060,010
-124,700
-11% -$1.01M 0.23% 43
2021
Q3 		$11.8M Sell
1,184,710
-1,433,326
-55% -$35.3M 0.41% 31
2021
Q2 		$80.9M Buy
2,618,036
+84,401
+3% +$2.71M 3.02% 10
2021
Q1 		$111M Hold
2,533,635
– – 4.9% 7
2020
Q4 		$117M Buy
+2,533,635
New +$84.6M 6.31% 4

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

EcoR1 Capital's SPRY Position: Q3 2022 in Review

EcoR1 Capital sold out of ARS Pharmaceuticals (SPRY) in Q3 2022, closing a stake of 575,359 shares — an estimated $2.44M sold.

EcoR1 Capital first reported a position in SPRY in Q4 2020 and held it in 7 quarters. The position peaked at $117M in Q4 2020. 61 funds tracked by Wall St. Rank hold SPRY as of Q3 2022.

  • EcoR1 Capital reported no remaining ARS Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • EcoR1 Capital sold 575,359 ARS Pharmaceuticals shares in Q3 2022, an estimated $2.44M.
  • EcoR1 Capital first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • EcoR1 Capital's ARS Pharmaceuticals position peaked at $117M in Q4 2020.
  • 61 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2022.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.